Allotted, called up and fully paid	2025 £		2024 £
80 Ordinary A shares of £1.00 each	80		80
5 Ordinary B shares of £1.00 each	5		5
5 Ordinary C shares of £1.00 each	5		5
5 Ordinary D shares of £1.00 each	5		5
5 Ordinary E shares of £1.00 each	5		5
	100		100

Share capital rights
The A ordinary shares carry full voting, dividend and capital rights; the B, C, D and E ordinary shares carry rights to dividends only.

The comparative figures for the year ended 31 October 2024 have been restated to correct errors in the financial statements previously approved. Amounts received in advance from customers for credits not yet used had been recognised as turnover on receipt rather than as the services were delivered; the cost of contractor services delivered in October 2024 but invoiced and paid in November 2024 had not been accrued; certain costs paid in advance had not been treated as prepayments; and one customer invoice had been included in turnover and trade debtors twice. The effect on the year ended 31 October 2024 is to reduce turnover by £108,805, increase administrative expenses by £91,762, and reduce profit before tax by £200,566 from £207,466 to £6,900. The tax charge of £32,764 previously reported has been replaced by a charge of £4,884, comprising tax payable under section 455 CTA 2010 on a loan to a director of £1,049 and deferred tax of £3,835, being a liability of £18,354 on accelerated capital allowances (of which £934 arose in the previous period and had not been provided) less an asset of £14,519 on the trading loss now available for carry forward; the corporation tax paid for the year is recoverable and is shown within debtors at 31 October 2025. Profit after tax for the year ended 31 October 2024 is reduced by £172,686 to £2,016 and net assets at 31 October 2024 by the same amount, from £223,647 to £50,961. The profit and loss reserve at 1 November 2023 is unchanged. The profit and loss reserve at 1 November 2024 of £223,547 as previously reported is reduced by the prior period adjustment of £172,686 to £50,861 as restated; the loss for the year of £5,341 and dividends of £26,260 bring the reserve to £19,260 at 31 October 2025. 

Dr Valeed Ghafoor: balance owed to the company at 1 November 2024 £3,107; advances during the year £13,180; amounts credited (use of home) £624; balance at 31 October 2025 £15,663 (2024: £3,107); maximum balance during the year £16,287. The loan is unsecured, interest free and repayable on demand. The balance was not repaid within nine months of the year end and tax under section 455 CTA 2010 of £4,238 (2024: £1,049) is included in creditors.

During the year the company wrote off a loan of £15,550 (2024: balance £15,550) due from Future Doctors Academy Ltd, a company of which Dr Valeed Ghafoor was a director and 25 to 50% shareholder, following its dissolution on 20 May 2025.


The Brooke Surgery, a GP practice of which Dr Valeed Ghafoor is a principal, is a customer of the company. Turnover from The Brooke Surgery in the year was £157,592 (2024: £150,001), on the company's standard terms. At 31 October 2025 the amount due from The Brooke Surgery was £nil (2024: £39,904) after unpaid balances of £616 on two invoices were written off in the year. 

Dividends paid £26,260 (2024: £2,500): A ordinary shares £24,100 (2024: £500); B, C, D and E ordinary shares £2,160 in total (2024: £2,000 declared, paid in the year ended 31 October 2025). The share classes carry different rights and the totals per class are given rather than amounts per share.

The hire purchase obligation of £26,975 is secured on the BYD Seal motor vehicle and is repayable by 48 monthly instalments of £343.49 to September 2028 followed by a final payment of £17,302.50.

Current tax £7,287, before the research and development expenditure credit of £12,495 set against it; tax under section 455 CTA 2010 £4,238; deferred tax charge £6,125 (including a credit of £3,145 from the change in rate) (2024: section 455 £1,049 and deferred tax charge £3,835, of which £934 related to the previous period). The tax under section 455 CTA 2010 is repayable to the company if and when the loan to the director is repaid, released or written off; no asset has been recognised because no repayment had been made at the date these financial statements were approved. 

The provision for deferred tax of £9,960 (2024: £3,835) comprises accelerated capital allowances of £9,960 (2024: £18,354) less tax losses of £nil (2024: £14,519). The asset on losses was released in the year as the losses were used against the profits of the year. Deferred tax is measured at 19%, the small profits rate enacted and expected to apply when the timing differences reverse (2024: 25%); the effect of the change in rate, a credit of £3,145, is included in the deferred tax charge for the year. Corporation tax recoverable within debtors £32,764 (2024: nil), being the tax paid for the year ended 31 October 2024 that is repayable following the amendment of that return.

At 31 October 2025 the company had total future minimum payments under a non-cancellable contract hire agreement for a motor vehicle of £36,090 (2024: £65,497), not provided in the financial statements. The agreement runs for 36 months from January 2025 at £1,336.67 a month, with 27 payments outstanding at 31 October 2025.

Operating profit is stated after charging exceptional items of £60,550 (2024: £nil), being amounts written off: a loan of £15,550 to Future Doctors Academy Ltd, which was dissolved on 20 May 2025, and £45,000 paid in the year ended 31 October 2024 to The Car Section Ltd and Cohiba Real Estate Ltd as informal investments, which the directors consider irrecoverable. Turnover is stated after deducting £25,361 in respect of invoices raised in the year ended 31 October 2024 which had already been settled in that year by receipts recorded as turnover, and administrative expenses include specific bad debts of £11,947 (2024: £nil) written off in respect of invoices raised in that year. 

The company's ultimate controlling party is Dr Valeed Ghafoor by virtue of his majority shareholding.